 |
|
Efalizumab for Patients With Moderate to Severe Plaque Psoriasis
A Randomized Controlled Trial
Kenneth B. Gordon, MD;
Kim A. Papp, MD;
Tiffani K. Hamilton, MD;
Patricia A. Walicke, MD;
Wolfgang Dummer, MD;
Nicole Li, PhD;
Brian W. Bresnahan, PhD;
Alan Menter, MD; for the Efalizumab Study Group
JAMA. 2003;290:3073-3080.
Context Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL).
Objective To assess the efficacy and safety of efalizumab, a T-cell modulator, in patients with plaque psoriasis.
Design, Setting, and Patients Phase 3 randomized, double-blind, parallel-group, placebo-controlled trial involving 556 adult patients with stable, moderate to severe plaque psoriasis and conducted at 30 study centers in the United States and Canada between January and July 2002.
Interventions Patients were randomly assigned in a 2:1 ratio to receive 12 weekly doses of subcutaneous efalizumab, 1 mg/kg (n = 369), or placebo equivalent (n = 187).
Main Outcome Measures At least 75% improvement on the Psoriasis Area and Severity Index (PASI-75); improvement on the overall Dermatology Life Quality Index (DLQI), Itching Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) at week 12 vs baseline.
Results Efalizumab-treated patients experienced significantly greater improvement on all end points than placebo-treated patients. Twenty-seven percent of efalizumab-treated patients achieved PASI-75 vs 4% of the placebo group ( P<.001). Efalizumab-treated patients exhibited significantly greater mean percentage improvement than placebo-treated patients on the overall DLQI (47% vs 14%; P<.001), Itching VAS (38% vs -0.2%; P<.001), and PSA frequency and severity subscales (48% vs 18% and 47% vs 17%, respectively; P<.001 for both) at the first assessment point. Efalizumab was safe and well tolerated, with primarily mild to moderate adverse events.
Conclusion In this 12-week study, efalizumab resulted in significant improvements in clinical end points, including physician-assessed and dermatology-specific patient-reported HRQL measures, in patients with moderate to severe plaque psoriasis.
Author Affiliations: Loyola University Medical Center, Maywood, Ill (Dr Gordon); Probity Medical Research, Waterloo, Ontario (Dr Papp); Atlanta Dermatology, Vein and Research Center LLC, Atlanta, Ga (Dr Hamilton); Genentech Inc, South San Francisco, Calif (Drs Walicke, Dummer, Li, and Bresnahan); and Baylor University Medical Center, Dallas, Tex (Dr Menter).
RELATED ARTICLES
A Promising Step Forward in Psoriasis Therapy
Robert S. Stern
JAMA. 2003;290(23):3133-3135.
EXTRACT
| FULL TEXT
Psoriasis
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2003;290(23):3160.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go
Gelfand
Arch Dermatol 2007;143:1191-1193.
FULL TEXT
Efalizumab-Associated Papular Psoriasis
Hassan et al.
Arch Dermatol 2007;143:900-906.
ABSTRACT
| FULL TEXT
Ectopic lymphoid neogenesis in psoriatic arthritis
Canete et al.
Ann Rheum Dis 2007;66:720-726.
ABSTRACT
| FULL TEXT
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek et al.
Postgrad. Med. J. 2007;83:251-260.
ABSTRACT
| FULL TEXT
AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes
Shimaoka et al.
Proc. Natl. Acad. Sci. USA 2006;103:13991-13996.
ABSTRACT
| FULL TEXT
Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab.
Weinberg and Siegfried
Arch Dermatol 2006;142:555-558.
FULL TEXT
Impaired Langerhans cell migration in psoriasis
Cumberbatch et al.
J. Exp. Med. 2006;203:953-960.
ABSTRACT
| FULL TEXT
Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways
Garrood et al.
Rheumatology (Oxford) 2006;45:250-260.
FULL TEXT
An Overview of the Pharmacokinetics and Pharmacodynamics of Efalizumab: A Monoclonal Antibody Approved for Use in Psoriasis
Joshi et al.
J Clin Pharmacol 2006;46:10-20.
ABSTRACT
| FULL TEXT
Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis
Jordan
The Annals of Pharmacotherapy 2005;39:1476-1482.
ABSTRACT
| FULL TEXT
TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE
Coffey et al.
Drug Metab. Dispos. 2005;33:623-629.
ABSTRACT
| FULL TEXT
Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis
Mortensen et al.
J Clin Pharmacol 2005;45:286-298.
ABSTRACT
| FULL TEXT
Psoriasis pathophysiology: current concepts of pathogenesis
Krueger and Bowcock
Ann Rheum Dis 2005;64:ii30-ii36.
ABSTRACT
| FULL TEXT
Targeting leukocyte integrins in human diseases
Yonekawa and Harlan
J. Leukoc. Biol. 2005;77:129-140.
ABSTRACT
| FULL TEXT
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Menter et al.
Arch Dermatol 2005;141:31-38.
ABSTRACT
| FULL TEXT
The Binding Sites for Competitive Antagonistic, Allosteric Antagonistic, and Agonistic Antibodies to the I Domain of Integrin LFA-1
Lu et al.
J. Immunol. 2004;173:3972-3978.
ABSTRACT
| FULL TEXT
In Vitro Internalization, Intracellular Transport, and Clearance of an Anti-CD11a Antibody (Raptiva) by Human T-Cells
Coffey et al.
J. Pharmacol. Exp. Ther. 2004;310:896-904.
ABSTRACT
| FULL TEXT
A Promising Step Forward in Psoriasis Therapy
Stern
JAMA 2003;290:3133-3135.
FULL TEXT
|
